Introduction:
Last Updated 5 August 2010Venous thromboembolism (VTE) comprises both deep vein
thrombosis (DVT) and pulmonary embolism (PE) and represents a significant
public health and financial burden. There is a large unmet need in the VTE
therapy market for safer, more-predictable anticoagulants. The launch of
several key oral therapies, coupled with shifts in physician prescribing
practices, will drive significant market growth over the 2008-2018 forecast
period.
Questions Answered in This Report:
*
Several novel anticoagulants will launch by 2013 for the
treatment, secondary prophylaxis, and/or primary prophylaxis of VTE.
Rivaroxaban (Bayer/Ortho-McNeil’s Xarelto), dabigatran etexilate (Boehringer
Ingelheim’s Pradaxa), and apixaban (Bristol-Myers Squibb/Pfizer) will be the
most successful.
What rate of uptake will these agents experience, and how
extensive will their penetration of the VTE market be? What impact will these
novel oral anticoagulants have on the use of current therapies?
*
The new oral agents could streamline patient care and VTE
management, but the efficacy and long-term use of current therapies such as
vitamin K antagonists and low-molecular-weight heparins act as substantial
barriers to novel agents’ uptake.
Will the novel agents be able to overcome
these barriers? Which agents are best positioned to offer improved efficacy or
strong safety profiles that will displace established agents?
*
Levels of anticoagulant drug use in various patient populations
at risk of developing VTE are suboptimal. Anticipated shifts in prescribing
practices are set to change this situation, driving up rates of prophylaxis.
Which
VTE patient populations will benefit most from increased anticoagulant drug
use? How will these changes shape the market potential of the emerging
therapies?Scope:
Markets covered: United States, France, Germany,
Italy, Spain, United Kingdom, Japan.
Primary research: 30 country-specific interviews with
thought leaders/experts.
Epidemiology: Surgical and nonsurgical prophylaxis;
acute treatment and secondary prophylaxis.
Population segments in market forecast: Prophylaxis
market: major orthopedic surgery, other major and minor surgery, and
nonsurgical patients. Acute treatment and secondary prophylaxis market: deep
vein thrombosis, pulmonary embolism.
Emerging therapies: Phase II: 7 drugs; Phase III: 7
drugs; registered: 2 drugs. Coverage of 12 select preclinical and Phase I
products.
Alternative market scenarios: (1) Bristol-Myers Squibb
and Pfizer choose not to launch apixaban in the United States for the primary
prophylaxis of VTE following major orthopedic surgery, (2) Boehringer Ingelheim
launches dabigatran etexilate for the primary prophylaxis of VTE in hospitalized
medically ill patients, (3) rivaroxaban fails to gain approval in the United
States for a VTE indication.